It appears that the treatment of obese rats with ZnONPs inhibits the progression of endothelial dysfunction, as evidenced by a reduction in the aortic tunica thickening, fibroid necrosis in the aorta, foam cells, and plasma levels of MCP-1, resistin, and CRP. This evidence concerns the gene CRP and endothelial dysfunction.